SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-11-30
- Last Posted Date
- 2023-10-24
- Target Recruit Count
- 366
- Registration Number
- NCT05631262
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study of Intratumoral KL340399 in Patients with Advanced Solid Tumors
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2024-12-09
- Target Recruit Count
- 30
- Registration Number
- NCT05549804
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A Study of KL130008 in Adults With Severe Alopecia Areata
- First Posted Date
- 2022-08-11
- Last Posted Date
- 2022-08-11
- Target Recruit Count
- 176
- Registration Number
- NCT05496426
- Locations
- 🇨🇳
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangzhou, China
A Study of KL340399 in Patients With Advanced Solid Tumors
- First Posted Date
- 2022-05-24
- Last Posted Date
- 2024-06-27
- Target Recruit Count
- 30
- Registration Number
- NCT05387928
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A Study of SKB315 in Patients With Advanced Solid Tumors
- First Posted Date
- 2022-05-10
- Last Posted Date
- 2023-10-24
- Target Recruit Count
- 206
- Registration Number
- NCT05367635
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-04-28
- Last Posted Date
- 2023-12-14
- Target Recruit Count
- 110
- Registration Number
- NCT05351788
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, China
SKB264 Injection Vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2024-12-12
- Target Recruit Count
- 254
- Registration Number
- NCT05347134
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing, China
🇨🇳Jiangsu Province Hospital, Nanjing, Jiangsu, China
A Study of KL590586 in Patients With Advanced Solid Tumors
- First Posted Date
- 2022-03-03
- Last Posted Date
- 2024-06-25
- Target Recruit Count
- 414
- Registration Number
- NCT05265091
- Locations
- 🇨🇳
Sichuan Kelun Botai Biopharmaceutical Co., Chengdu, Sichuan, China
Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2024-08-05
- Target Recruit Count
- 688
- Registration Number
- NCT04835142
- Locations
- 🇨🇳
307 Hospital of PLA, Beijing, Beijing, China
Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody Trial
- First Posted Date
- 2018-02-08
- Last Posted Date
- 2018-02-08
- Target Recruit Count
- 570
- Registration Number
- NCT03426371
- Locations
- 🇨🇳
307 Hospital of PLA, Beijing, Beijing, China
© Copyright 2024. All Rights Reserved by MedPath